W L van Putten
About
In The Last Decade
W L van Putten
21 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 107
- Obstetrics and Gynecology 1.3k
- Reproductive Medicine 1.0k
- Cancer Research 937
- Oncology 929
- Molecular Biology 786
Countries citing papers authored by W L van Putten
This map shows the geographic impact of W L van Putten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W L van Putten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W L van Putten more than expected).
Fields of papers citing papers by W L van Putten
This network shows the impact of papers produced by W L van Putten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W L van Putten. The network helps show where W L van Putten may publish in the future.
Co-authorship network of co-authors of W L van Putten
This figure shows the co-authorship network connecting the top 25 collaborators of W L van Putten. A scholar is included among the top collaborators of W L van Putten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W L van Putten. W L van Putten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas. | 37 |
| 2 | Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial breakdown → | 775 |
| 3 | Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial breakdown → | 1302 |
| 4 | 2 | |
| 5 | 50 | |
| 6 | 128 | |
| 7 | 49 | |
| 8 | 104 | |
| 9 | Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. | 95 |
| 10 | Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. | 155 |
| 11 | Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). | 26 |
| 12 | 185 | |
| 13 | 77 | |
| 14 | c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. | 177 |
| 15 | Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. | 196 |
| 16 | Mechanical ventilation in cancer patients. Analysis of clinical data and outcome. | 21 |
| 17 | 151 | |
| 18 | 0 | |
| 19 | Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. | 190 |
| 20 | Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. | 103 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.